KCNQ2 and colorectal cancer: Downregulation of KCNQ2 was reported to be correlated with oxaliplatin-induced trigeminal neuropathic pain that occurs in the majority of advanced colorectal cancer patients receiving oxaliplatin-based chemotherapy, and the potentiator retigabine of KCNQ2 alleviated neuropathic pain in rat models[10].